Non-classic apparent mineralocorticoid excess is an underrecognized cause of low-renin hypertension, which is often misdiagnosed as essential hypertension. This condition challenges traditional classifications and highlights the need for mechanism-based diagnostics and medical care.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Shah, S. S., Fuller, P. J., Young, M. J. & Yang, J. Update on low-renin hypertension: current understanding and future direction. Hypertension 81, 2038–2048 (2024).
Shah, S. S. et al. Prevalence and characteristics of low-renin hypertension in a primary care population. J. Endocr. Soc. 8, bvae113 (2024).
Baudrand, R. & Vaidya, A. The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int. J. Mol. Sci. 19, 546 (2018).
Carvajal, C. A., Tapia-Castillo, A., Vecchiola, A., Baudrand, R. & Fardella, C. E. Classic and nonclassic apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 105, dgz315 (2020).
Tapia-Castillo, A. et al. Clinical, biochemical and genetic characteristics of “non-classical” apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104, 595–603 (2019).
Yau, M. et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Proc. Natl Acad. Sci. USA 114, E11248–E11256 (2017).
Carvajal, C. A. et al. Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type-2 deficiency. Am. J. Hypertens. 31, 910–918 (2018).
Carvajal, C. A., Tapia-Castillo, A., Uslar, T. & Fardella, C. E. in Hydro Saline Metabolism: Epidemiology, Genetics, Pathophysiology, Diagnosis and Treatment (eds M. Caprio & F. L. Fernandes-Rosa) 31–349 (Springer International Publishing, 2023).
Adler, G. K. et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 110, 2453–2495 (2025).
Shah, S. S. et al. Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. J. Hum. Hypertens. 38, 383–392 (2024).
Acknowledgements
The authors acknowledge the support of grants ANID-FONDECYT 1212006 (C.A.C.), ICM-ANID ICN2021_045 (C.A.C., C.E.F.), 11251675 (A.T.-C.), ANILLO ACT 210039 (R.B.), SOCHED 2024-06 (A.T.-C.) and CETREN-UC 2024 (C.A.C., C.E.F.).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Carvajal, C.A., Tapia-Castillo, A., Uslar, T. et al. Driving hypertension: non-classic apparent mineralocorticoid excess. Nat Rev Endocrinol (2025). https://doi.org/10.1038/s41574-025-01209-6
Published:
Version of record:
DOI: https://doi.org/10.1038/s41574-025-01209-6
